Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Paul Harris, CFA
EssilorLuxotticaESLOYPAST TOP PICKJun 15, 2023
Paul Harris, CFAOwned
$91.14
Stock price when the opinion was issued
$101.92
As of Jun 18, 2026. Market Open.
Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
TOP PICK
Lenses plus frames. Has a lock on the whole value chain. Purchase of Grant Vision will dramatically change its business over the next several years. Use of lenses has increased because of aging demographics plus faster eye deterioration from computer screens. Also a fashion statement. Great technology. Yield is 1.7%.
(Analysts’ price target is $109.40)Paul Harris, CFAOwned
Healthcare
PAST TOP PICK
(A Top Pick Sep 30/21, Down 19%) A global leader in design, manufacturing and distribution of eyeglasses as well as frames and has a high market share. Eye wear has an attractive long term growth profile. It is clear where management is heading.
Paul Harris, CFAOwned
Healthcare
PAST TOP PICK
(A Top Pick Aug 24/21, Down 19%) It is a leader in the design, manufacturing and distribution of lenses, frames and sunglasses. Has a great balance sheet and should have good growth for the next few years. It acquired Grand Vision, mostly European, which changed the dynamics of the company and helps them to have a broader digital component. Has a 2.3% dividend.
Paul Harris, CFAOwned
Healthcare
PAST TOP PICK
(A Top Pick Jul 22/21, Down 11%) Whole spectrum of eyewear business. Screen time has increased demand for kids' eyewear. Demographic play for older adults. Balance sheet getting better. Designer brands. Corporate governance improved.
Paul Harris, CFAOwned
Healthcare
TOP PICK
price target N/A The global leader in optical frames, lens and sunglasses. The eyewear business is long-term resilient and will grow. A great demographic play, too. Over the last two years, screen use has soared and has caused a lot of eye problems. They bought Grand Vision, which is transformational in a digital way. Pays a 2.3X dividend. Strong balance sheet and cash flow growth will rise.
Paul Harris, CFAOwned
Healthcare
PAST TOP PICK
(A Top Pick May 07/21, Up 14%) Believes company is in process of optimization previous mergers.
Covid-19 pandemic has had adverse affect on company, which created a good buying opportunity.
As economy re-opens the company will do well.
Continues to own the stock.
Norman LevineOwned
Healthcare
TOP PICK
Designer, manufacturer, and distributor of lenses, frames, and sunglasses. Market leader. Huge retail presence in Europe and NA. Really strong growth. Strong online presence. Recent acquisition will be transformational. Great story at these levels. Yield is 0.66%.
Paul Harris, CFAOwned
Healthcare
TOP PICK
Price target: 169.22 Euros A merger of a French lens company and an Italian frame company, including brands Ray Banz, Chanel, Prada and Oakley, The lens business is stable and amounts to 66% of their revenues. The merger wasn't easy, but he expects $500 million in cut costs. They bought Grand Vision, and its 7,000 European stores to make them a major player in lenses and frames. Now, their online sales are nearly #1 in this space. The only business where they lack are contact lenses. ESLOY is well-integrated, with many of their businesses #1 in their categories. There's a trend of people needing glasses because of looking at TV and computer screens.
Paul Harris, CFAOwned
Healthcare
TOP PICK
Largest global designer, manufacturer, distributor of lenses in the world. Also does frames and sunglasses. These businesses are resilient and have strong growth going forward. Owns franchises such as LensCrafters and Ray-Ban. GrandVision acquisition will be important. Great balance sheet. Yield is 0.71%.
Paul Harris, CFAOwned
Healthcare
TOP PICK
Merger of the largest lense maker Essilor with the almost monopolistic maker of eyeware frames Luxotica. Together it is a behemoth. They dominate the market and is also the biggest retailer of eyecare with Pearlvision, LenseCrafters, SunglassHut. Huge in sunglasses too. A return to normal stock. (Analysts’ price target is $179.18)
Norman LevineOwned
Healthcare
Great growth from a demographic point of view. Largest player in the world in this area. Almost like an oligopoly, especially in making lenses. Really good lens technology, very innovative. Great story. Buy here and still do well.